Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Adverse events
Event No.
Prolonged respiratory suppression (>20 seconds) 39 (1.9%)
Minimal respiratory suppression (10–19 seconds) 119 (5.9%)
Hyperventilation (>25/min) 34 (1.7%)
Other 53 (2.6%)
    Nausea/vomiting 11 (0.5%)
    Anxiety/funny feeling 7 (0.3%)
    Agitation 6 (0.3%)
    Hypertension 5 (0.2%)
    Numbness/tingling 4 (0.2%)
    Blurry vision 4 (0.2%)
    Decreased/impaired level of consciousness 4 (0.2%)
    Limb jerking/tremor 2 (0.1%)
    Seizure 2 (0.1%)
    Taste disturbance 2 (0.1%)
    TIA-like symptoms 2 (0.1%)
    Bradycardia to asystole 1 (0.05%)
    Dyspnea 1 (0.05%)
    Desaturation to 80 seconds 1 (0.05%)
    Chest tightness 1 (0.05%)
    Respiratory insufficiency 1 (0.05%)
    Could not tolerate mask 1 (0.05%)
    Headache 1 (0.05%)
    Claustrophobia 1 (0.05%)
Severity 
    Mild 35 (1.7%)
    Moderate 10 (0.5%)
    Severe 7 (0.3%)
Event required termination of study 12

Event	No.
Prolonged respiratory suppression (>20 seconds)	39 (1.9%)
Minimal respiratory suppression (10–19 seconds)	119 (5.9%)
Hyperventilation (>25/min)	34 (1.7%)
Other	53 (2.6%)
Nausea/vomiting	11 (0.5%)
Anxiety/funny feeling	7 (0.3%)
Agitation	6 (0.3%)
Hypertension	5 (0.2%)
Numbness/tingling	4 (0.2%)
Blurry vision	4 (0.2%)
Decreased/impaired level of consciousness	4 (0.2%)
Limb jerking/tremor	2 (0.1%)
Seizure	2 (0.1%)
Taste disturbance	2 (0.1%)
TIA-like symptoms	2 (0.1%)
Bradycardia to asystole	1 (0.05%)
Dyspnea	1 (0.05%)
Desaturation to 80 seconds	1 (0.05%)
Chest tightness	1 (0.05%)
Respiratory insufficiency	1 (0.05%)
Could not tolerate mask	1 (0.05%)
Headache	1 (0.05%)
Claustrophobia	1 (0.05%)
Severity
Mild	35 (1.7%)
Moderate	10 (0.5%)
Severe	7 (0.3%)
Event required termination of study	12